Beijing Xinbo Technology Trading Co., Ltd.

: !: /, , : ) % absorbed after oral administration, half-life is about hours, and is mainly eliminated by C metabolism. The oral bioavailability is approximately %, and peak plasma concentration is reached after several hours. Pharmacokinetic analysis of the patient receiving monotherapy showed that it takes days to reach stable blood concentration. The patient's age, weight, and gender have no significant relationship with the drug clearance rate. Smoking can increase the drug clearance rate by %. c=c>
<: /, , ) b : !: /, , : ) [Indications] c=c>
<: /, , ) b : !: /, , : ) For the third-line treatment of locally advanced or metastatic non-small cell lung cancer that has failed two or more chemotherapy regimens. c=c>
<: /, , ) b : !: /, , : ) [Contraindications] It is prohibited for those who are allergic to this product and its ingredients. c=c>
<: /, , ) b : !: /, , : ) [Adverse reactions] c=c>
<: /, , ) b : !: /, , : ) The most common adverse reactions were rash and diarrhea, the incidence rates of rash and diarrhea were % and % respectively, the median onset time of rash was days, and the median onset time of diarrhea was days. c=c>
<: /, , ) b : !: /, , : ) Adverse reactions with an incidence rate greater than % include: rash, diarrhea, decreased appetite, fatigue, dyspnea, cough, nausea, infection, Vomiting, stomatitis, itching, dry skin, conjunctivitis, keratoconjunctivitis, abdominal pain.